Geode Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Geode Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,995	Closed	-$3K	–	4151
2017 Q4	$3K	Hold	10,995	–	–	﹤0.01%	4021
2017 Q3	$4K	Hold	10,995	–	–	﹤0.01%	4049
2017 Q2	$9K	Hold	10,995	–	–	﹤0.01%	4078
2017 Q1	$34K	Hold	10,995	–	–	﹤0.01%	4003
2016 Q4	$22K	Sell	10,995 -1	-0%	-$3	﹤0.01%	3997
2016 Q3	$51K	Hold	10,996	–	–	﹤0.01%	3912
2016 Q2	$101K	Hold	10,996	–	–	﹤0.01%	3804
2016 Q1	$127K	Hold	10,996	–	–	﹤0.01%	3768
2015 Q4	$156K	Hold	10,996	–	–	﹤0.01%	3762
2015 Q3	$184K	Hold	10,996	–	–	﹤0.01%	3713
2015 Q2	$207K	Hold	10,996	–	–	﹤0.01%	3576
2015 Q1	$213K	Hold	10,996	–	–	﹤0.01%	3557
2014 Q4	$321K	Hold	10,996	–	–	﹤0.01%	3387
2014 Q3	$391K	Buy	10,996 +5,520	+101%	+$213K	﹤0.01%	3274
2014 Q2	$245K	Hold	5,476	–	–	﹤0.01%	3448
2014 Q1	$267K	Hold	5,476	–	–	﹤0.01%	3404
2013 Q4	$202K	Buy	5,476 +774	+16%	+$73.3K	﹤0.01%	3430
2013 Q3	$483K	Hold	4,702	–	–	﹤0.01%	2971
2013 Q2	$365K	Buy	+4,702	New	+$450K	﹤0.01%	3012

Other funds holding IMUC

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

FAAS

First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's IMUC Position: Q1 2018 in Review

Geode Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2018, closing a stake of 10,995 shares — an estimated $3K sold.

Geode Capital Management first reported a position in IMUC in Q2 2013 and held it in 19 quarters. The position peaked at $483K in Q3 2013. 23 funds tracked by Wall St. Rank hold IMUC as of Q1 2018.

Geode Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2018 after selling out during the quarter.
Geode Capital Management sold 10,995 ImmunoCellular Therapeutics, Ltd. shares in Q1 2018, an estimated $3K.
Geode Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 19 quarters.
Geode Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $483K in Q3 2013.
23 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2018.

Based on Geode Capital Management's 13F filing for Q1 2018, filed 15 May 2018.